| Not Yet Recruiting | Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer NCT07525349 | Assiut University | — |
| Recruiting | Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology NCT06417190 | Leslie Ballas | Phase 2 |
| Recruiting | Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study NCT07339761 | University of Aarhus | N/A |
| Recruiting | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy NCT07234968 | Thomas Jefferson University | N/A |
| Recruiting | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (N NCT06571708 | Columbia University | Phase 2 |
| Recruiting | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment NCT06537154 | Peter Black | Phase 2 / Phase 3 |
| Recruiting | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer NCT06470282 | University of California, San Francisco | Phase 1 / Phase 2 |
| Recruiting | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease NCT06529822 | Washington University School of Medicine | Phase 1 |
| Recruiting | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552 | Vasgene Therapeutics, Inc | Phase 2 / Phase 3 |
| Recruiting | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy NCT06290687 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Ca NCT06263153 | Yuanquan Yang | Phase 2 |
| Not Yet Recruiting | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer NCT06528483 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Active Not Recruiting | Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt NCT05776758 | Regina Elena Cancer Institute | Phase 3 |
| Recruiting | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients NCT06341400 | Zhujiang Hospital | Phase 1 / Phase 2 |
| Recruiting | Prophylactic Antibiotics in Cystectomy With Diversion NCT06190197 | University of Minnesota | EARLY_Phase 1 |
| Recruiting | Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer NCT05833867 | Shilpa Gupta, MD | Phase 1 |
| Not Yet Recruiting | Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer NCT06325423 | Assiut University | — |
| Recruiting | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial NCT06257017 | Yung NA | Phase 2 |
| Recruiting | Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers NCT06537960 | Hopital Foch | N/A |
| Active Not Recruiting | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemora NCT05975307 | Sun Yat-sen University | Phase 2 |
| Withdrawn | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N NCT05564416 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer NCT06074484 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Ca NCT05581589 | University of Washington | Phase 2 |
| Recruiting | The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer NCT06215976 | Cairo University | Phase 4 |
| Recruiting | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladd NCT05203913 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 |
| Recruiting | Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) NCT05790850 | University of Virginia | N/A |
| Completed | ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy NCT05630131 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug S NCT05767528 | Chinese PLA General Hospital | — |
| Withdrawn | FL- 101 Study in Non-Metastatic MIBC NCT05395260 | Flame Biosciences | EARLY_Phase 1 |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Active Not Recruiting | Pembrolizumab in Muscle-invasive Bladder Cancer NCT05406713 | Matthew Galsky | Phase 2 |
| Unknown | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer NCT05297552 | RemeGen Co., Ltd. | Phase 2 |
| Active Not Recruiting | Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach NCT05295992 | Varian, a Siemens Healthineers Company | N/A |
| Terminated | Clinical Performance Evaluation of the C2i-Test NCT05221827 | C2i Genomics | — |
| Unknown | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy NCT04876313 | IRCCS San Raffaele | Phase 2 |
| Unknown | Clinical Utility of VI-RADS in Diagnosis of MIBC NCT05097404 | Samsung Medical Center | — |
| Unknown | Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic NCT04966130 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Stu NCT05028660 | Elypta | — |
| Unknown | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Ca NCT04909775 | Ruijin Hospital | Phase 2 |
| Recruiting | Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Musc NCT04724928 | University Hospital, Ghent | Phase 2 |
| Recruiting | Robotic Radical Cystectomy Outcomes NCT04900558 | University of Florence | — |
| Unknown | a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder C NCT04686149 | Yonsei University | — |
| Completed | Addressing Barriers to Palliative Care Use in Bladder Cancer NCT04598724 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Active Not Recruiting | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer NCT04506554 | Fox Chase Cancer Center | Phase 2 |
| Completed | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer NCT04383743 | University of Washington | Phase 2 |
| Completed | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC NCT04610671 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Can NCT03775265 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy NCT02145390 | University of Miami | N/A |
| Recruiting | Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy NCT06170177 | IRCCS San Raffaele | — |